Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTC PINK OTC PINK Primary 
Healthineers: Reviewing Q2 And Updating My Targets (Rating Upgrade)
Siemens Healthineers reported strong Q2 '25 results, with 7% top-line growth and confirmed full-year outlook, despite challenges in China and tariffs. The company excels in imaging, holding a 37% market share, and its Varian acquisition boosts its radiotherapy segment, though diagnostics remain a challenge. Valuation is attractive at sub-€48/share, with a price target of €53/share, offering a potential upside of 14-25% annually.
Siemens Healthineers Posts Profit, Revenue Rise; Adjusts Guidance on Tariff Uncertainty
The healthcare-equipment company posted a rise in net profit and revenue for its fiscal second quarter but widened its adjusted earnings per share range on increased tariff uncertainty.
Siemens Healthineers posts revenue beat, but lowers floor of profit outlook
German medical technology group Siemens Healthineers posted second quarter revenue slightly above market expectations on Wednesday, but brought down the lower end of its annual earnings forecast due to trade barriers and increased tariffs.
Siemens Healthineers and Vivolight Medical Collaborate to Launch DSA-OCT Integrated Multi-Modal Diagnostic and Treatment Platform, Ushering in a New Era of Intelligent Cath Labs
Shenzhen, China--(Newsfile Corp. - February 28, 2025) - Recently, the world's first DSA-OCT integrated multi-modal diagnostic and treatment platform (ARTIS icono floor), jointly developed by Siemens Healthineers and Vivolight Medical , has been officially installed at Zhongshan Hospital, affiliated with Fudan University in Shanghai, China. This marks a new era in the precision treatment of coronary heart disease.
Siemens sells 2% stake in Siemens Healthineers
German engineering company Siemens announced late on Wednesday it launched a sale of a 2% stake in healthcare subsidiary Siemens Healthineers.
Siemens Healthineers says it would welcome stake reduction by Siemens
Siemens Healthineers' CEO said on Thursday that the medical-technology company had a "very positive" view on considerations by parent Siemens to reduce its stake.
Siemens Healthineers reports Q1 revenue slightly above consensus
German medical technology company Siemens Healthineers on Thursday reported first quarter revenue slightly above consensus, as its U.S. revenues increased by 16% while those from China declined 6% due to "continued delays in customer orders."
Siemens Healthineers Digital Transformation Strategies, Innovation Programs and Technology Initiatives
The report provides insights into Siemens Healthineers' tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. The report provides insights into Siemens Healthineers' tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
Kromek to swing into profit after winning Siemens Healthineers deal for CZT detection
Kromek Group PLC said it has signed a non-exclusive deal with Siemens Healthineers that should lead it to become profitable this year and slash debt. The radiation and bio-detection detection specialist signed a set of agreements with Siemens Medical Solutions USA, known as Siemens Healthineers, for a total of $37.5 million (ÂŁ30.2m) in cash, including a first instalment of $25 million to be paid this year.
InkSpace Imaging Receives FDA 510(k) Clearance for 1.5T 24-channel MR Coil for Siemens Healthineers
PLEASANTON, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- InkSpace Imaging, a leader in MRI coil innovation, today announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging's next-generation 1.5 Tesla (1.5T) 24-channel MR coil for Siemens Healthineers Magnetom MRI scanners.
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
– Combines Profound's TULSA-PRO ® and Siemens Healthineers' Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers, a global leader in medical technology, pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound's TULSA-PRO® system and consumables with Siemens Healthineers' Magnetom Free.Max magnetic resonance (“MR”) scanner.1 The Transurethral Ultrasound Ablation (“TULSA”) procedure, performed using Profound's TULSA-PRO® system, employs real-time MR guidance for precision to preserve prostate disease patients' urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA-PRO® enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low-, intermediate, or high-risk prostate cancer; with benign prostatic hyperplasia (“BPH”); as well as those prostate cancer patients on active surveillance seeking treatment of their cancer and relief from their symptoms of BPH.
Siemens Healthineers Offers Imaging-Driven Upside For Patient Investors
Recent underperformance is likely due to below-expectations revenue, mixed margins, and lower fiscal 2025 guidance, despite strong imaging and radiation oncology performance. Imaging remains a major growth driver, as new medical interventions and screening programs drive screening demand and tools like AI become increasingly vital. Fiscal 2025 guidance was modestly disappointing, but long-term growth in imaging, oncology, and image-guided therapies supports a positive outlook.
